Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.
Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.
The injectable formulation can cut administration time from two or more hours to just five minutes.
Those with blood cancers are nine times more likely to be hospitalized or die from the flu.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
Here are latest arrivals approved by the Food and Drug Administration.
More than 80% of clinical trial participants experienced complete or partial remission.
New drugsto treat multiple myeloma are producing better results for patients, with fewer side effects.
Here’s a list of the approved drugs to treat multiple myeloma. Click on any of the medications for more info on dosing, side effects...
The antibody-drug-conjugate produced an overall response rate of 31%.
Researchers identify a series of molecular abnormalities associated with greater risk of myeloma progression
O. David Dye, 77, a multiple myeloma survivor who lives in Troy, Alabama, is training to be a master gardener.
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.